Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
Organizer:

The HIV pandemic continues to impose tremendous morbidity, mortality, and economic burden globally. Meanwhile, innovative prevention modalities such as microbicides, PrEP, long-lasting ARV and monoclonal antibody injectables are providing novel tools for prevention. In addition, the HIV vaccine research field has evolved greatly since 2009 when RV144 first demonstrated empirical evidence that a vaccine could prevent HIV transmission, albeit modestly. This session will explore the latest in vaccine design, development, and testing, with a focus on current trials on an efficacy pathway, as well as promising approaches in pre- or early clinical trials. Three state-of-the-art presentations on the vaccine pipeline, including passive immunization, promising vector-platforms, and the development of envelope proteins able to elicit broadly neutralizing antibodies will be followed by a moderated discussion on the scientific priorities, challenges, and opportunities for next generation vaccines.

17:00
SUSA2201
Introduction
Gabriella Scarlatti, Italy
Slides
17:05
SUSA2202
An HIV vaccine: Can we end the HIV pandemic without one and, if not, how do we get one?
Anthony Fauci, United States
Slides
17:30
SUSA2203
Exploiting novel cellular immunity in HIV prevention: Development of a prophylactic HIV vaccine based on Cytomegalovirus (CMV) vectors
Louis Picker, United States
17:50
SUSA2204
Novel envelope proteins to induce neutralizing antibodies
Rogier Sanders, Netherlands
18:10
SUSA2205
Panel Discussion
Jon Cohen, United States
Maureen Goodenow, United States
Yves Lévy, France
Nyaradzo Mavis Mgodi, Zimbabwe
Nina Russell, United States
Hanneke Schuitemaker, Netherlands